24Oct 2023
Risk-conferring HLA variants in an epilepsy cohort: benefits of multifaceted use of whole genome sequencing in clinical practice

Risk-conferring HLA variants in an epilepsy cohort: benefits of multifaceted use of whole genome sequencing in clinical practice

In a groundbreaking study, researchers utilized whole genome sequencing data to identify pharmacogenomic risk factors linked to antiseizure medication-induced cutaneous adverse drug reactions (cADRs). Analyzing Genomics England's 100,000 Genomes Project data, they found 4 HLA-B15:02 and 86 HLA-A31:01 carriers among 1043 epilepsy patients. One HLA-B15:02 carrier experienced cADRs. Notably, 16.9% of European HLA-A31:01 carriers and 14.4% of carriers, regardless of ancestry, suffered cADRs. The study highlights the vast potential of genetic data in healthcare beyond identifying disease-causing variants. Understanding pharmacogenomic biomarkers can personalize pharmacotherapy, offering tailored treatment for genetically susceptible individuals. This research opens avenues for individually customized diagnostic and therapeutic care in healthcare.

  • #neurology

Like

Save

Share